An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : AS1411
Phase: Phase 2
Ages Eligible For Study:
- primary refractory or relapsed AML - confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002) - aged at least 18 years